ACTICOR BIOTECH overview

University of Birmingham and Acticor Biotech News Release Limited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attacks February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction. In 2022, the University of Birmingham and...

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in the United-States, Europe, Israel and United Kingdom Confirmation of clinical results communication for the second quarter 2024 Paris, France, November 07, 2023 - 08h00 CET - ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the...

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024 Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028 Paris, France, September 14, 2023 - 5.45 pm CEST - Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug...

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of July 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority). Listing Place: Euronext Growth...

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023: - 43,423...

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of June 30, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority). Listing Place: Euronext Growth Paris ISIN Code...

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of May 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority). Listing Place: Euronext Growth Paris ISIN Code...

Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, is discussing with the FDA and the EMA its development program for the acute ischemic stroke (AIS) indication. In the US, Acticor Biotech was granted FDA Type C consultation on its non-clinical and clinical developments for its first-in-class drug candidate, glenzocimab. Written responses were...